Serologicals Corporation has announced completed its previously announced acquisition of Cytomyx Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc.
Based in Cambridge, U.K., Cytomyx Ltd. is a provider of ion channel cell lines and drug discovery services. With 23 distinct ion channel cell lines commercially
available, and more in its pipeline, Cytomyx Ltd. offers a large portfolio of distinct ion channel cell lines.
Serologicals paid U.S. $7 million for the stock of Cytomyx Ltd.
“We are very pleased to announce the completion of the Cytomyx Ltd. acquisition,” said David A. Dodd, President and CEO of Serologicals. “Ion channels represent the third largest target class for Biopharma research and drug development today. The expertise that Cytomyx Ltd. brings will greatly enhance our drug discovery products and services portfolio with therapeutically relevant ion channel cell lines and ion channel screening services. With GPCRs, kinases, and ion channels, Serologicals will better serve the needs of our Biopharma customers through a comprehensive portfolio offering.”